Amylyx Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $3.04B
- P/E (TTM)
- –
- Dividend yield
- –
About Amylyx Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies for endocrine disorders and neurodegenerative diseases. Its pipeline includes avexitide, an investigational glucagon-like peptide-1 receptor antagonist undergoing evaluation for post-bariatric hypoglycemia and congenital hyperinsulinism. The company also advances AMX0035 for Wolfram syndrome, AMX0114 for amyotrophic lateral sclerosis, and AMX0318 for metabolic and rare conditions. Because its drug candidates remain in clinical and preclinical development, the company currently serves patient populations and study participants affected by these underserved medical conditions rather than commercial consumers.
The company conducts clinical trials across multiple medical centers, including twenty-one study sites in the United States for its lead trial. Its research initiatives, academic partnerships, and patent rights span international jurisdictions, including the United States, Canada, and Europe. Amylyx contracts external manufacturing organizations for the clinical production and packaging of its investigational products. The provided text does not identify the location of the company's corporate headquarters.
Summary of the business section of Amylyx Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Amylyx Pharmaceuticals, Inc.
- Headquarters
- Cambridge, MA
- Address
- 55 Cambridge Parkway, Suite 6w 02142
- Phone
- (617) 682-0917
- Employees
- 136, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- AMLX
- Exchange
- Nasdaq
- IPO date
- Jan 10, 2022
- Shares outstanding
- 111M, Jul 27, 2026
- Public float
- $518.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1658551
- CUSIP
- 03237H101
- ISIN
- US03237H1014
- EIN
- 46-4600503
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Justin B. Klee | Co-Chief Executive Officer, Director | 3,614,495 |
| Joshua B. Cohen | Co-Chief Executive Officer, Director | 3,614,042 |
| Gina Mazzariello | Chief Legal Officer | 190,838 |
| Camille L. Bedrosian | Chief Medical Officer | 278,064 |
| James M. Frates | Chief Financial Officer | 333,625 |
| Karen Firestone | Director | 116,900 |
| Bernhardt G. Zeiher | Director | 10,000 |
| George M. Milne Jr | Director | 812,881 |
| Daphne Quimi | Director | 5,000 |
| Paul R. Fonteyne | Director | 3,947 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Joshua Cohen | $2.72M | $12.27M | $1.47M | $67 | – |
| FY2025 Justin Klee | $2.72M | $12.27M | $1.47M | $67 | – |
| FY2024 Joshua Cohen | $6.50M | $1.03M | $2.42M | $21 | – |
| FY2024 Justin Klee | $6.50M | $1.03M | $2.42M | $21 | – |
| FY2023 Joshua Cohen | $7.42M | -$6.40M | $3.09M | $81 | – |
| FY2023 Justin Klee | $7.42M | -$6.40M | $3.09M | $81 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 136 full-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 10, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 10, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 4, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |